Unknown PHASE1 INTERVENTIONAL 1-arm NCT03976856

Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

A Phase Ib Clinical Study With Extension Phase to Evaluate Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib in the Treatment of Relapsed or Metastatic NSCLC Patients

Sponsor: Genor Biopharma Co., Ltd.

Conditions Metastatic Non-small Cell Lung Cancer

Interventions Fruquintinib GB226

Updated 9 times since 2019 Last updated: Mar 2, 2021 Started: Jul 23, 2019 Primary completion: Dec 31, 2021 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03976856, this PHASE1 trial focuses on Metastatic Non-small Cell Lung Cancer and remains ongoing. Sponsored by Genor Biopharma Co., Ltd., it has been updated 9 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Apr 2023 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Apr 2021 — Apr 2023 [monthly]

Recruiting PHASE1
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE1

▶ Show 4 earlier versions

Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Jan 2020 — Sep 2020 [monthly]

Recruiting PHASE1
Dec 2019 — Jan 2020 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jul 2019 — Dec 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genor Biopharma Co., Ltd.
Hutchison Medipharma Limited

Data source: Genor Biopharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China